NCT02802748 - Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions

Breast Cancer

Interventions

DRUG

Oral Vinorelbine

Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc

DRUG

Letrozole

Letrozole will be administered orally at 2.5 mg QD for 3 weeks.

Trial Locations (10)

Hospital de León, León

Hospital Universitario Ramón y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Clínica Quirón Sagrado Corazón, Seville

Hospital Universitari Sant Joan de Reus, Reus

Fundación Instituto Valenciano de Oncología, Valencia

Hospital Clínico Universitario de Valencia, Valencia

Hospital Clínico Universitario Lozano Blesa, Zaragoza

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Clínic de Barcelona, Barcelona